Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show, Webcast

Arcus Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference


Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time in New York, NY.

A live audio webcast of the presentation will be available by visiting the "Investors" section of the Arcus website at www.arcusbio.com. A replay of the webcast will be available for at least 30 days following the live event.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly-differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. AB928, the first and only dual adenosine A2a/A2b receptor antagonist in the clinic, is being evaluated in several Phase 1b/2 studies across multiple indications, including prostate, colorectal, non-small cell lung, pancreatic, triple negative breast and renal cell cancers. AB680, the first CD73 small-molecule inhibitor in the clinic, is in Phase 1/1b development for the treatment of first-line metastatic pancreatic cancer. AB154, an anti-TIGIT monoclonal antibody, is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with zimberelimab and AB928. Zimberelimab (AB122), Arcus's anti-PD1 monoclonal antibody, is being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD1 treatment options, as well as in combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences


These press releases may also interest you

at 01:10
Envision Energy Explores the Future of Green Hydrogen Fuel Adoption at Singapore Maritime Week
Envision Energy, a global leader in green technology, introduced its groundbreaking green hydrogen fuel solutions for the first time at Singapore Maritime Week, held from April 16 to April 19 in Singapore, exploring the new frontier of green fuel...

at 01:05
KKR and Impilo Announce Strategic Partnership Together With Management in Rare Disease Platform Immedica Pharma
Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care...

at 01:05
BenevolentAI Provides an Update on Its Business Priorities
Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces an update on its business priorities. Going forward the Company...

at 01:05
Largest Chinese Trade Delegation in Years Secures Cooperative Intentions in New Zealand
On April 19, Ren Hongbin, Chairman of the China Council for the Promotion of International Trade (CCPIT) and the China Chamber of International Commerce (CCOIC), concluded a delegation's visit to New Zealand. The visit, highlighted by a session...

at 01:01
Electroceuticals/Bioelectric Medicine Market to Reach $40.5 Billion, Globally, by 2032 at 7.4% CAGR: Allied Market Research
Allied Market Research published a report, titled, "Electroceuticals/Bioelectric Medicine Market by Product (Cardiac Pacemakers and Implantable Cardioverter Defibrillators, Cochlear Implants, Spinal Cord Stimulators, Deep Brain Stimulators, Vagus...

at 01:00
Imparta Launches World's First Sales Methodology-Aware AI
Imparta Ltd, a global leader in performance improvement for customer-facing teams, has announced the release of i-Coach AI, the world's first sales methodology-aware AI....

More news about Science and technology...


News published on and distributed by: